This study investigates Padeliporfin VTP for treating unresectable pancreatic adenocarcinoma.
The purpose of this study is to evaluate the safety and preliminary effectiveness of Padeliporfin VTP. This involves a process where a light-sensitive drug is activated to target cancer cells.
- Who can participate: Participants must be 18 years or older with Stage III pancreatic ductal adenocarcinoma and have a tumor deemed unresectable.
- Study details: Participants will receive Padeliporfin VTP, which involves a special light treatment.